Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -7 of 7
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
12/9/2008
 
First Published:
1/11/2008
1.
Phase I/II Pilot Study of a Nonmyeloablative Conditioning Regimen Comprising Anti-CD45 Monoclonal Antibody, Alemtuzumab, Fludarabine Phosphate , and Low-Dose Total-Body Irradiation Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients With High-Risk Hematological Diseases
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Biomarker/Laboratory analysis, Treatment
Active
Under 100
Other
BCM-H-12472
H 12472, BCM-ACHE, NCT00056966
2.
Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL) Given With CD45 Monoclonal Antibody (MAb) in Patients With Epstein Barr Virus (EBV) -Positive Nasopharyngeal Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
Not specified
Other
20996
DELLA, NCT00515957
Last Modified:
10/9/2008
 
First Published:
1/29/2008
3.
Phase I Study of a Conditioning Regimen Comprising Anti-CD45 Monoclonal Antibody, Alemtuzumab, and Fludarabine Followed By Allogeneic Stem Cell Transplantation in Pediatric Patients With Severe Combined Immunodeficiency Disease or Other Primary Immunodeficiency Disorder
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
Under 18
Other
BCM-H-21123
H 21123, BCM-MASCI, NCT00609258
Last Modified:
5/19/2008
 
First Published:
1/31/2008
4.
Phase I Study of Anti-CD45 Monoclonal Antibody and Autologous or Syngeneic LMP1- and LMP2-Specific Cytotoxic T-Lymphocytes in Patients With Relapsed Epstein-Barr Virus (EBV)-Positive Hodgkin Lymphoma, Non-Hodgkin Lymphoma, or EBV-Associated T-/Natural Killer-Lymphoproliferative Disorders
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Biomarker/Laboratory analysis, Treatment
Active
Any age
Other
BCM-H19275
H 19275, BCM-ALDI, NCT00608478
Last Modified:
10/9/2008
 
First Published:
1/14/2008
5.
Phase I Study of Anti-CD45 Monoclonal Antibody, Cytarabine, Cyclophosphamide, and Total-Body Irradiation With or Without Alemtuzumab in Patients Undergoing Allogeneic Stem Cell Transplantation For Advanced Leukemia or Other Hematologic Malignancy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
45 and under
Other
BCM-H-12870
H 12870, BCM-ADVL, NCT00601380
Last Modified:
12/9/2008
 
First Published:
1/31/2008
6.
Phase I Study of Anti-CD45 Monoclonal Antibody, 14g2a.zeta Chimeric Receptor Transduced Autologous Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes, and 14g2a.zeta Transduced Autologous Peripheral Blood T cells in Patients With Advanced Neuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Biomarker/Laboratory analysis, Treatment
Active
3 to 64
Other
BCM-H-13149
H 13149, BCM-NESTLES, NCT00609206
7.
A Phase I Trial Evaluating the Administration of Epstein Barr Virus (EBV)-Specific Cytotoxic T-Lymphocytes (CTLs) to Patients With Recurrent or Metastatic EBV-Positive Nasopharygneal Cancer (NPC)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
18 and over
Other
NPC-CTL
OCRN #03-NOV-0422, NCT00706316
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute